Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Glioblastoma 7Urinary Bladder Neoplasms 5Glioma 5Prostatic Neoplasms 4Lung Neoplasms 4Esophageal Neoplasms 4Burkitt Lymphoma 4Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Oropharyngeal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Astrocytoma 3Uterine Cervical Neoplasms 2Sarcoma, Ewing 2Sarcoma 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Mouth Neoplasms 2Mesothelioma, Malignant 2Melanoma 2Laryngeal Neoplasms 2Gliosarcoma 2Ganglioneuroblastoma 2Brain Neoplasms 2Adenocarcinoma of Lung 2Wilms Tumor 1Vulvar Neoplasms 1Vaginal Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

pembrolizumab 1X-Rays 1Taxes 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Congresses as Topic 1Cisplatin 1Carboplatin 1Brachytherapy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Cervical Adenocarcinoma × Radiation × 30 days × Clear all
NCT07061977 2026-06-05

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
336 enrolled
Gynecologic

Locally Advanced Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡